Biological Subtype Predicts Risk of Locoregional Recurrence after Mastectomy and Impact of Postmastectomy Radiation in a Large National Database Presented in part at the 56th Annual Meeting of the American Society for Radiation Oncology, San Francisco, CA, September 14-17, 2014.

International Journal of Radiation Oncology Biology Physics

Volumn 93, Issue 3, 2015, Pages 622-630

  Tseng, Yolanda D ^a   Uno, Hajime ^b   Hughes, Melissa E ^b   Niland, Joyce C ^c   Wong, Yu Ning ^d   Theriault, Richard ^e   Blitzblau, Rachel C ^f   Moy, Beverly ^g   Breslin, Tara ^h   Edge, Stephen B ^i,j   Hassett, Michael J ^b   Punglia, Rinaa S ^k  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Lake Forest Hospital   (United States)

ⁱ BAPTIST CANCER CENTER   (United States)

^j VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODIES; ONCOLOGY;

BREAST CARCINOMAS; LOCAL THERAPY; LOCOREGIONAL RECURRENCE; METHODS AND MATERIALS; MULTI VARIABLES; NATIONAL DATABASE; RADIATION ONCOLOGY; TRIPLE NEGATIVE;

RADIOTHERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; BREAST CANCER; BREAST CARCINOMA; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CONFERENCE PAPER; DISTANT METASTASIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; LOCAL THERAPY; LOCOREGIONAL RECURRENCE; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; FACTUAL DATABASE; MULTICENTER STUDY; PATHOLOGY; PROPENSITY SCORE; RISK ASSESSMENT; TIME FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPENSITY SCORE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; TIME FACTORS; TRASTUZUMAB; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84942311708     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.07.006     Document Type: Conference Paper

References (25)

1. C.M. Perou, T. Sorlie, M.B. Eisen, and et al. Molecular portraits of human breast tumours Nature 406 2000 747 755
2. T. Sørlie, C.M. Perou, R. Tibshirani, and et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
3. T. Sørlie, R. Tibshirani, J. Parker, and et al. Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 2003 8418 8423
4. T.O. Nielsen, F.D. Hsu, K. Jensen, and et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374
5. L.A. Carey, C.M. Perou, C.A. Livasy, and et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2006 2492 2502
6. M. Kyndi, F.B. Sørensen, H. Knudsen, and et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish breast cancer cooperative group J Clin Oncol 26 2008 1419 1426
7. J.E. Panoff, J. Hurley, C. Takita, and et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation Breast Cancer Res Treat 128 2011 899 906
8. S.G. Wu, Z.Y. He, Q. Li, and et al. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy Breast 21 2012 657 661
9. A. Goldhirsch, W.C. Wood, A.S. Coates, and et al. Strategies for subtypes - dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011 Ann Oncol 22 2011 1736 1747
10. M.C. Cheang, S.K. Chia, D. Voduc, and et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 2009 736 750
11. M.M. Kim, S. Dawood, P. Allen, and et al. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer Cancer 118 2012 4936 4943
12. E.H. Romond, E.A. Perez, J. Bryant, and et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
13. I.J. Dahabreh, H. Linardou, F. Siannis, and et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials Oncologist 13 2008 620 630
14. A.P. Kiess, H.L. McArthur, K. Mahoney, and et al. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer Cancer 118 2012 1982 1988
15. R. Gelman, R. Gelber, I.C. Henderson, and et al. Improved methodology for analyzing local and distant recurrence J Clin Oncol 8 1990 548 555
16. R.J. Gray A class of k-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
17. Z. Gabos, J. Thoms, S. Ghosh, and et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer Breast Cancer Res Treat 124 2010 187 194
18. K.D. Voduc, M.C. Cheang, S. Tyldesley, and et al. Breast cancer subtypes and the risk of local and regional relapse J Clin Oncol 28 2010 1684 1691
19. L.S. Dominici, E.A. Mittendorf, X. Wang, and et al. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy Breast Cancer Res 14 2012 R82
20. J. Selz, D. Stevens, L. Jouanneau, and et al. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy Int J Radiat Oncol Biol Phys 84 2012 1123 1132
21. P.T. Truong, B.T. Sadek, M.F. Lesperance, and et al. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy? Int J Radiat Oncol Biol Phys 88 2014 57 64
22. M.C. Kneubil, J. Brollo, E. Botteri, and et al. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction Eur J Surg Oncol 39 2013 260 265
23. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, and et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
24. W. Foulkes, M. Grainge, E. Rakha, and et al. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status Breast Cancer Res Treat 117 2009 199 204
25. H. In, K. Bilimoria, A. Stewart, and et al. Cancer recurrence: An important but missing variable in national cancer registries Ann Surg Oncol 21 2014 1520 1529